Hatatian Fatemeh, Babakhani Farzad, Gudarzi Hoda, Momenifar Navid, Norouzi Mehdi, Shafieifar Mina, Kakavandi Ehsan, Sadeghi Ahmadreza, Sharbatdar-Alaei Hedyeh, Farahmand Mohammad, Amiri-Roudy Maedeh, Jahantigh Hamid Reza, Madihi Mobina, Borhani Kiandokht, Ajorloo Mehdi, Hedayat Yaghoobi Mojtaba
Inflammation and Inflammatory Disease Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Iran J Public Health. 2020 Nov;49(11):2136-2143. doi: 10.18502/ijph.v49i11.4731.
Hemodialysis (HD) patients and kidney transplant (KT) recipients are exposed to be infected by blood-borne viruses (BBVs). Current study was conducted to evaluate the prevalence of BBVs in HD and KT patients in the whole Iranian population.
From Jan 2016 to Dec 2017, 174 hemodialysis and 139 kidney transplant recipients enrolled in this survey. After blood sampling, serum samples were detected for HBV, HCV, HCMV, HIV and HTLV antibodies. Seropositive samples confirmed by Polymerase chain reaction (PCR) method.
Overall, 6 (3.44%) and 3 (2.15%) of hemodialysis-dependent and transplantation patients had evidence of HCV infection, whereas no patients were HIV and HBV positive, two cases (1.14%) of hemodialysis and one case (0.71%) of transplantation patients demonstrated the HTLV-1 infection. 52 (37.4%) of patients received graft were positive for HCMV antibody. In addition, our study showed a co-infection of HCMV with HCV (3 patients, 2.15%) in transplantation patients.
Prevalence of BBVs infection was lower in comparison to the previous studies. The current strict infection control practices in Iran appear to be effective in limiting dialysis and related infections after transplantation. Because BBVs infections constantly occur especially in dialysis and after transplantation units, our data will be useful to build a new strategic plan for the elimination of BBVs infection in kidney therapycenters.
血液透析（HD）患者和肾移植（KT）受者有感染血源性病毒（BBV）的风险。本研究旨在评估伊朗全体人群中HD和KT患者的BBV感染率。
2016年1月至2017年12月，174名血液透析患者和139名肾移植受者参与了本调查。采血后，检测血清样本中的乙肝病毒（HBV）、丙肝病毒（HCV）、人巨细胞病毒（HCMV）、人类免疫缺陷病毒（HIV）和人类嗜T淋巴细胞病毒（HTLV）抗体。血清学阳性样本通过聚合酶链反应（PCR）方法进行确认。
总体而言，依赖血液透析的患者中有6例（3.44%）、移植患者中有3例（2.15%）有丙肝病毒感染的证据，而没有患者的HIV和HBV呈阳性，血液透析患者中有2例（1.14%）、移植患者中有1例（0.71%）显示有HTLV-1感染。接受移植的患者中有52例（37.4%）HCMV抗体呈阳性。此外，我们的研究显示移植患者中有HCMV与HCV的合并感染（3例，2.15%）。
与之前的研究相比，BBV感染率较低。伊朗目前严格的感染控制措施似乎在限制透析及移植后相关感染方面是有效的。由于BBV感染持续发生，尤其是在透析和移植科室，我们的数据将有助于制定一项新的战略计划，以消除肾脏治疗中心的BBV感染。
